Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Adherence of stable COPD patients to inhaled pharmacotherapy Source: Annual Congress 2011 - COPD management Year: 2011
The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002
Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study Source: ERJ Open Res, 6 (1) 00246-2019; 10.1183/23120541.00246-2019 Year: 2020
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Screening of inhalation technique and treatment adherence of COPD, asthma and ACO patients Source: International Congress 2019 – Inhalers: adherence and preference Year: 2019
Magnetocardiographic assessment of therapeutic efficacy of β2–agonists and corticosteroids in patients with COPD and bronchial asthma Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma Year: 2008
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013
Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study. Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021
The efficacy of incentive spirometry in COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 256s Year: 2002
Acute bronchodilator response does not predict health outcomes in patients with COPD treated with tiotropium Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Evaluation of the individual bronchodilator response in patients with severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
What influences the response to training of inhalation technique in patients with asthma and COPD? Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 240s Year: 2002
Modelling the beneficial impact of inhaled corticosteroids on health outcomes among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004
Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019
Compliance of COPD patients to their treatment Source: Eur Respir J 2003; 22: Suppl. 45, 244s Year: 2003